Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biden Signs ‘Historic’ $1.9Tn COVID-19 Relief Package Boosting Funding For Diagnostics, PPE

“This historic legislation is about rebuilding the backbone of this country,” the US president says

Executive Summary

The monies are primarily allocated to helping Americans facing economic hardships due to the pandemic, but also includes tens of billions to bolster COVID-19 testing efforts.

You may also be interested in...

Minute Insight: HHS Gets $35M Shot In Arm To Expand Telehealth For Family Planning

The US Department of Health and Human Services said on 23 November that the money will be used “to enhance and expand the telehealth infrastructure and capacity of Title X family planning providers.”

US Sen. Duckworth Prods FEMA To Help Overstocked PPE Reach Potential Users

The Illinois senator pointed to an apparent mismatch between ongoing reports of equipment shortages, and alleged stockpiles of unsold masks.

How Biden’s $1.9Tn Stimulus Bill Will Impact Medtech

Congress supports $1.9tn economic stimulus package, including billions extra in COVID-19 testing and supplies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts